Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;33(6):e14171.
doi: 10.1111/dth.14171. Epub 2020 Sep 7.

Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review

Layal Antoury  1 , Nolan J Maloney  1 , Daniel Q Bach  1 , Carolyn Goh  1 , Kyle Cheng  1
Affiliations
Review

Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review

Layal Antoury et al. Dermatol Ther. 2020 Nov.

Abstract

Immune checkpoint inhibitors (ICI) improve the ability of the immune system to target cancer cells by blocking signaling through either the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death (PD-1) receptor, or its ligand (PD-L1). They have been found to cause a variety of immune-related adverse events (irAEs) including a form of nonscarring alopecia that resembles alopecia areata (AA) in presentation and histology. Clinical features of ICI-induced AA are poorly described. We queried the Pubmed database for cases of AA secondary to ICI use reporting on extent of hair loss, treatments attempted, alopecia outcome, and time of follow-up with 13 cases identified. Although most patients had localized hair loss with subsequent regrowth, four of them experienced extensive and persistent AA, lasting up to a year. All but one patient continued ICI after the onset of hair loss. Many used topical corticosteroids with varying outcomes. Possible prognostic factors for severe and persistent disease may include young age and male sex. However, the low number of reported cases limits the generalizability of these findings. Tumor response was positive in every case of immune-induced AA where it was reported. Further investigation will be needed to better characterize clinical features of this irAE, risk factors for persistent disease, and determine its optimal management.

Keywords: alopecia areata; atezolizumab; immune checkpoint inhibitor; immune-related adverse event; ipilimumab; irAE; nivolumab; pembrolizumab.

PubMed Disclaimer

References

REFERENCES

    1. Yang W, Li S, Yang Q. Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98(20):e15731. https://doi.org/10.1097/MD.0000000000015731.
    1. Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990-997. https://doi.org/10.1016/j.jaad.2018.10.062.
    1. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45-51. https://doi.org/10.1001/jamadermatol.2015.2707.
    1. Zarbo A, Belum V, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176:1649-1652. https://doi.org/10.1111/bjd.15237.
    1. Ito T. Immune checkpoint inhibitor-associated alopecia areata. Br J Dermatol. 2017;176(6):1444-1445. https://doi.org/10.1111/bjd.15591.

Substances